Germline mutations in DNA repair genes are prevalent in myeloma patients and correlate with duration of response to a frontline genotoxic therapy.
The 2025 ASCO Annual Meeting is The Place to Be — a global gathering where oncology professionals connect, collaborate, and inspire. Known for advancing
The abstract will be released to the public on June 1, 2025 at 12:00 PM UTC Yelena Janjigian Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer…
The abstract will be released to the public on June 1, 2025 at 12:00 PM UTC Nicholas Turner Royal Marsden Hospital, London, United Kingdom Nicholas…
The abstract will be released to the public on June 1, 2025 at 12:00 PM UTC Andrew Kuykendall Moffitt Cancer Center, Tampa, FL Andrew Kuykendall,…
1 – 20 out of 139 Results for “myeloma” 139 Results Select All Presenter: Ross Firestone, MD, PhD Presenter: Claudio Cerchione, MD, PhD First Author:…
The abstract will be released to the public on June 1, 2025 at 12:00 PM UTC Jean Bourhi s CHUV, Bâtiment Hospitalier, Lausanne, Switzerland Jean…
The abstract will be released to the public on June 1, 2025 at 12:00 PM UTC Frank Sinicrope Mayo Clinic Rochester, Rochester, MN Frank Sinicrope,…
Journal of Patient-Centered Research and Reviews (JPCRR) is an open access, peer-reviewed medical journal founded in 2014 by Wisconsin-based Aurora Health Care, now a part…
A new targeted therapy aimed specifically at FGFR3, TYRA-300, is showing preliminary promise in patients with advanced FGFR3 -altered bladder cancer. Partial responses have been…
Program: Oral and Poster Abstracts Type: Oral Session: 907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes Hematology Disease Topics &…
